Company news
Aditxt, Inc. news in 2024
Aditxt, Inc.'s news releases, calls and decks from 2024, newest first.
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 11, 2024
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 7, 2024
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 30, 2024
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11: 30 AM Eastern Time
October 29, 2024
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 27, 2024
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11: 30 AM Eastern Daylight Time
October 8, 2024
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
October 7, 2024
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 2, 2024
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
September 26, 2024
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 19, 2024
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
September 8, 2024
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
September 3, 2024
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
August 25, 2024
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 20, 2024
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
August 12, 2024
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 8, 2024
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 24, 2024
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
July 16, 2024
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
May 2, 2024
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 1, 2024
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
January 29, 2024
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
January 7, 2024
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
January 4, 2024
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
January 1, 2024